REG - Oxford Biomedica PLC - AGM Update

Oxford BioMedicaAnnouncement

Wed 07:05

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250611:nRSK3639Ma&default-theme=true

RNS Number : 3639M  Oxford Biomedica PLC  11 June 2025

 

 

 

AGM Update

-      Annual General Meeting being held at 3pm BST today at Windrush
Court, Oxford, UK

-     The Company remains on track to deliver the outlook set out in the
Preliminary Results published on 9 April 2025

 

Oxford, UK - 11 June 2025: OXB (LSE: OXB) ("the Company"), a global quality
and innovation-led cell and gene therapy CDMO, provides an update to coincide
with its Annual General Meeting being held at 3pm BST today at Windrush Court,
Oxford, UK.

 

OXB has demonstrated strong commercial momentum and made good operational and
commercial progress in the year 2025 to date, as it continues to provide viral
vector manufacturing services to a diversified portfolio of clients. The
Company remains on track to deliver the outlook set out in the Preliminary
Results for the year ended 31 December 2024, published on 9 April 2025
(https://otp.investis.com/clients/uk/oxford_biomed1/rns/regulatory-story.aspx?cid=544&newsid=1927065)
.

 

Dr. Frank Mathias, Chief Executive Officer of OXB, commented: "We have
delivered strong operational performance so far in the first half of the year,
reflecting disciplined execution across our global sites and sustained
commercial momentum. The Company reiterates its financial guidance today and
remains focused on supporting clients across all stages of development.  OXB
remains confident in its near and medium-term targets as set out earlier this
year."

 

A corporate presentation will be given at the AGM by Dr. Frank Mathias, Chief
Executive Officer and Dr. Lucinda Crabtree, Chief Financial Officer of OXB. No
new material information will be disclosed.  For details of upcoming
financial events, please refer to the Company's investor calendar
(https://oxb.com/investor-events/) at https://oxb.com/investor-events/.

 

-Ends-

 

Enquiries:

 

OXB:

Sophia Bolhassan, Head of Investor Relations - T: +44 (0) 1865 509 737 / E:
ir@oxb.com (mailto:ir@oxb.com)

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
TetraVecta™ system), a dual-plasmid system for AAV production, suspension
and perfusion process using process enhancers and stable producer and
packaging cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUAVVRVKUNARR